Therapeutic class overview psoriasis

Report: THERAPEUTIC CLASS OVERVIEW PSORIASIS Category: Healthcare

Insert Image Height - 3.60 Width – 4.98

www.researchonglobalmarkets.com

Report: THERAPEUTIC CLASS OVERVIEW PSORIASIS Report Insights

• Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients pain, function and quality of life • Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients • The lack of targeted immune therapies other than TNF- inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc) www.researchonglobalmarkets.com

Report: THERAPEUTIC CLASS OVERVIEW PSORIASIS Report Insights (Continued)

• Pfizer launched the first oral Rheumatoid Arthritis (RA) drug –Xeljanz in 2012 for patients with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics • In the last couple of years, the face of healthcare has been changing due to challenges - quality and its affordability and accessibility to the providers and patients • There is ample room for an efficacious affordable therapy to tap the mild to moderate RA patients population where biologics have not made a dent www.researchonglobalmarkets.com

Report: THERAPEUTIC CLASS OVERVIEW PSORIASIS Report Insights (Continued)

• Few potential launches are also expected in 2014-2015 (OTEZLA apremilast, Xeljanz - tofacitinib) and onwards

www.researchonglobalmarkets.com

Report: THERAPEUTIC CLASS OVERVIEW PSORIASIS Table of Contents

• Executive Summary • Unmet Need in Psoriasis • Specific Unmet Need and Emerging Therapies • Pipeline - Biologics Products • Pipeline - Oral Treatment • Pipeline - Topical Treatments • Commercial Outlook • Disease Overview • Current Treatment Options • Treatment Guidelines For PsA www.researchonglobalmarkets.com

Report: THERAPEUTIC CLASS OVERVIEW PSORIASIS Report Details

• • • • • • • • •

Publish date: Feb 24, 2014 Geographic coverage: Global Number of Pages: 55 Available format: PDF, CD, Hardcopy Price for Single User License: USD 1,500 Price for Site License: USD 3,002 Price for Global User License: USD 4,502 Delivery Time: Within 1 business day Payment Modes: Credit/Debit Card, RTGS/Wire Transfer, Google Wallet, PayPal www.researchonglobalmarkets.com

Interested in this report?

To view more details regarding this premium market research report, Please click here

For further information, get in touch with us: E-mail: support@researchonglobalmarkets.com Call: US: +1 866 325 7446 UK: +44 203 514 2363 Others: +91 22 4098 7600 About Us Research on Global Markets is a leading source for market research on various sectors globally offering premium research content from worldwide publishers of market research reports Industry Segments Automotive & Transport

Consumer goods

Agriculture

Food and Beverage

Energy and Utilities

Public Sector

Manufacturing & Construction

Healthcare

Media & Entertainment

IT, Telecom & Electronics

Services

Others

www.researchonglobalmarkets.com